ATE205085T1 - Spirooxathiolan-quinuclidin-derivat zur behandlung von xerostomie - Google Patents
Spirooxathiolan-quinuclidin-derivat zur behandlung von xerostomieInfo
- Publication number
- ATE205085T1 ATE205085T1 AT95304449T AT95304449T ATE205085T1 AT E205085 T1 ATE205085 T1 AT E205085T1 AT 95304449 T AT95304449 T AT 95304449T AT 95304449 T AT95304449 T AT 95304449T AT E205085 T1 ATE205085 T1 AT E205085T1
- Authority
- AT
- Austria
- Prior art keywords
- xerostomia
- salivary gland
- alkyl
- treatment
- therapeutic agent
- Prior art date
Links
- 206010013781 dry mouth Diseases 0.000 title abstract 4
- 208000005946 Xerostomia Diseases 0.000 title abstract 3
- UANSQQFYKHHDJM-KRWDZBQOSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]naphthalene-1-carboxamide Chemical compound C1=CC=C2C(C(N[C@@H]3C4CCN(CC4)C3)=O)=CC=CC2=C1 UANSQQFYKHHDJM-KRWDZBQOSA-N 0.000 title 1
- 239000003814 drug Substances 0.000 abstract 3
- 210000003079 salivary gland Anatomy 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 229940124597 therapeutic agent Drugs 0.000 abstract 2
- 208000030507 AIDS Diseases 0.000 abstract 1
- 208000031886 HIV Infections Diseases 0.000 abstract 1
- 208000037357 HIV infectious disease Diseases 0.000 abstract 1
- 208000019914 Mental Fatigue Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 abstract 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 1
- 230000003902 lesion Effects 0.000 abstract 1
- 230000017074 necrotic cell death Effects 0.000 abstract 1
- 238000001959 radiotherapy Methods 0.000 abstract 1
- 210000003296 saliva Anatomy 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000028327 secretion Effects 0.000 abstract 1
- 230000009885 systemic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Mechanical Treatment Of Semiconductor (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP6168982A JP2852608B2 (ja) | 1994-06-27 | 1994-06-27 | 口腔乾燥症治療剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE205085T1 true ATE205085T1 (de) | 2001-09-15 |
Family
ID=15878165
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT95304449T ATE205085T1 (de) | 1994-06-27 | 1995-06-22 | Spirooxathiolan-quinuclidin-derivat zur behandlung von xerostomie |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US5580880A (de) |
| EP (1) | EP0689836B1 (de) |
| JP (1) | JP2852608B2 (de) |
| KR (1) | KR100322042B1 (de) |
| AT (1) | ATE205085T1 (de) |
| AU (1) | AU707236B2 (de) |
| CA (1) | CA2152420A1 (de) |
| CY (1) | CY2290B1 (de) |
| DE (1) | DE69522511T2 (de) |
| DK (1) | DK0689836T3 (de) |
| ES (1) | ES2163474T3 (de) |
| IL (1) | IL114256A (de) |
| NO (1) | NO309454B1 (de) |
| TW (1) | TW401298B (de) |
| ZA (1) | ZA955317B (de) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9618341D0 (en) * | 1996-09-03 | 1996-10-16 | Scotia Holdings Plc | Method of treatment |
| JP4447685B2 (ja) * | 1999-01-14 | 2010-04-07 | 第一三共株式会社 | 皮膚乾燥症治療剤 |
| JP4909809B2 (ja) * | 1999-03-24 | 2012-04-04 | 生化学工業株式会社 | 人工唾液 |
| US20110150974A1 (en) * | 2004-08-06 | 2011-06-23 | Daiichi Pharmaceutical Co., Ltd. | Agent For Oral Mucosal Administration |
| JP2009506069A (ja) * | 2005-08-26 | 2009-02-12 | ブレインセルス，インコーポレイティド | ムスカリン性受容体調節による神経発生 |
| EP2258359A3 (de) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenese durch Modulation des Muscarinrezeptors mit Sabcomelin |
| US20070077300A1 (en) * | 2005-09-30 | 2007-04-05 | Wynn David W | Oral compositions containing a salivation inducing agent |
| CA2625153A1 (en) | 2005-10-21 | 2007-04-26 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
| US20070112017A1 (en) | 2005-10-31 | 2007-05-17 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| EP2377531A2 (de) | 2006-05-09 | 2011-10-19 | Braincells, Inc. | Neurogenese mittels Angiotensin-Modulation |
| US7678808B2 (en) | 2006-05-09 | 2010-03-16 | Braincells, Inc. | 5 HT receptor mediated neurogenesis |
| WO2008030651A1 (en) * | 2006-09-08 | 2008-03-13 | Braincells, Inc. | Combinations containing a 4-acylaminopyridine derivative |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| US20090053309A1 (en) * | 2007-08-24 | 2009-02-26 | Axiomedic Ltd., Gibraltar | Adhesive compositions for the treatment of xerostomia |
| US9161909B2 (en) * | 2007-08-24 | 2015-10-20 | Axiomedic Ltd. | Adhesive compositions for the treatment of xerostomia |
| US9884082B2 (en) | 2008-11-13 | 2018-02-06 | David A. Hamlin | Compositions and methods for alleviating hyposalivation and for providing oral comfort |
| US9597278B2 (en) | 2008-11-13 | 2017-03-21 | David A. Hamlin | Compositions and methods for alleviating hyposalivation and for providing oral comfort |
| US20100216805A1 (en) | 2009-02-25 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| US8450487B2 (en) * | 2010-06-08 | 2013-05-28 | Apicore, Llc | Process for the preparation of cis-2-methylspiro (1,3-oxathiolane 5-3′) quinuclidine |
| ES2913050T3 (es) | 2015-12-04 | 2022-05-31 | San Ei Gen Ffi Inc | Utilización de isoquercitrina modificada por enzima |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4855290A (en) * | 1985-05-10 | 1989-08-08 | State Of Israel, Represented By Prime Minister's Office, Israel Institute For Biological Research | Derivatives of quinuclidine |
| US5078129A (en) * | 1987-05-01 | 1992-01-07 | Research Foundation Of State University Of New York | Device for stimulating salivation |
| IL87234A (en) * | 1987-08-13 | 1992-02-16 | Israel Inst Biolog Res | Optical isomers of 2-methylspiro(1,3-oxathiolane-5,3')quinuclidine,their preparation and pharmaceutical compositions containing them |
| US4917674A (en) * | 1988-04-04 | 1990-04-17 | Molinoff Henry C | Mouth moisturizing device |
| US4906455A (en) * | 1988-04-15 | 1990-03-06 | Wm. Wrigley Jr. Company | Method for treating xerostomia employing chewing gum containing relatively insoluble, hydrophobic, food-grade organic acid |
| US4983378A (en) * | 1988-11-22 | 1991-01-08 | Parnell Pharmaceuticals, Inc. | Method and composition for treating xerostomia |
| US4997654A (en) * | 1989-08-14 | 1991-03-05 | Warner-Lambert Company | Method for increasing salivation for xerostomia patients |
| JP3018494B2 (ja) * | 1990-11-30 | 2000-03-13 | ソニー株式会社 | 特殊効果装置 |
| JP2683783B2 (ja) * | 1992-07-10 | 1997-12-03 | 雪印乳業株式会社 | シェーグレン症候群治療剤 |
-
1994
- 1994-06-27 JP JP6168982A patent/JP2852608B2/ja not_active Expired - Fee Related
-
1995
- 1995-06-06 US US08/466,373 patent/US5580880A/en not_active Expired - Lifetime
- 1995-06-10 KR KR1019950015296A patent/KR100322042B1/ko not_active IP Right Cessation
- 1995-06-21 TW TW084106358A patent/TW401298B/zh not_active IP Right Cessation
- 1995-06-21 IL IL11425695A patent/IL114256A/xx not_active IP Right Cessation
- 1995-06-21 AU AU23245/95A patent/AU707236B2/en not_active Ceased
- 1995-06-22 CA CA002152420A patent/CA2152420A1/en not_active Abandoned
- 1995-06-22 ES ES95304449T patent/ES2163474T3/es not_active Expired - Lifetime
- 1995-06-22 EP EP95304449A patent/EP0689836B1/de not_active Expired - Lifetime
- 1995-06-22 AT AT95304449T patent/ATE205085T1/de not_active IP Right Cessation
- 1995-06-22 DK DK95304449T patent/DK0689836T3/da active
- 1995-06-22 DE DE69522511T patent/DE69522511T2/de not_active Expired - Lifetime
- 1995-06-26 NO NO952561A patent/NO309454B1/no unknown
- 1995-06-27 ZA ZA955317A patent/ZA955317B/xx unknown
-
2002
- 2002-07-31 CY CY0200048A patent/CY2290B1/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NO309454B1 (no) | 2001-02-05 |
| DE69522511T2 (de) | 2002-05-16 |
| IL114256A (en) | 1999-05-09 |
| TW401298B (en) | 2000-08-11 |
| DK0689836T3 (da) | 2002-05-06 |
| CA2152420A1 (en) | 1995-12-28 |
| NO952561L (no) | 1995-12-28 |
| DE69522511D1 (de) | 2001-10-11 |
| JP2852608B2 (ja) | 1999-02-03 |
| CY2290B1 (en) | 2003-07-04 |
| JPH0812575A (ja) | 1996-01-16 |
| AU707236B2 (en) | 1999-07-08 |
| EP0689836A1 (de) | 1996-01-03 |
| ES2163474T3 (es) | 2002-02-01 |
| KR960000222A (ko) | 1996-01-25 |
| NO952561D0 (no) | 1995-06-26 |
| US5580880A (en) | 1996-12-03 |
| EP0689836B1 (de) | 2001-09-05 |
| IL114256A0 (en) | 1995-10-31 |
| KR100322042B1 (ko) | 2002-11-04 |
| ZA955317B (en) | 1996-02-02 |
| AU2324595A (en) | 1996-01-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE205085T1 (de) | Spirooxathiolan-quinuclidin-derivat zur behandlung von xerostomie | |
| ATE73331T1 (de) | Verwendung von tetrahydrobiopterinen zur herstellung eines medikaments zur behandlung von kinderautismus. | |
| HUP0302962A2 (hu) | Béta-karbolinszármazékok, ezeket a vegyületeket tartalmazó gyógyászati készítmények és a vegyületek alkalmazása | |
| EE05530B1 (et) | Gamma-aminov?ihappe derivaate sisaldavad tahked kompositsioonid ja nende saamise meetod | |
| ATE121939T1 (de) | Ascorbinsäure-tocopheryl-phosphatdiester zur hemmung der maillard-reaktion. | |
| FI932390A0 (fi) | Nya hydroxiaminsyra- och N-hydroxiureaderivat samt deras anvaendning | |
| MX9706380A (es) | Guanidinas de acidos alquenil-carboxilicos sustituidos con fenilo, procedimientos para su preparacion, su utilizacion como medicamento o agente de diagnostico, asi como un medicamento que las contiene. | |
| DE69615984D1 (de) | Verwendung von Ursolsäure zur Herstellung eines Arzneimittels zur Unterdrückung von Metastasen | |
| DE60317039D1 (de) | Peptidborsäuren und deren Verwendung in der Herstellung von Salzen derselben | |
| NO932520D0 (no) | Preparat for helbredelse av sykdommen sjoegren's syndrom | |
| ATE38991T1 (de) | In 2-stellung substituierte 1,3propyledendephosphonat-derivate, ihre herstellung und pharmazeutische zusammensetzungen, die sie enthalten. | |
| ATE79257T1 (de) | Verwendung von tetrahydrobenz(c,d>indol-6carboxamiden zur herstellung von arzneimitteln zur behandlung von angstzustaenden. | |
| FI933681A0 (fi) | Antimikrobiellt medel | |
| ATE311191T1 (de) | Apoptotische körper zur verwendung in der behandlung von t-zell-vermittelten- und entzündungserkrankungen | |
| ATE135573T1 (de) | Verwendung von indazol-methoxyalkansäure zur herstellung eines arzneimittels zur behandlung von autoimmunkrankheiten | |
| NO173137C (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive forbindelser | |
| ATE34662T1 (de) | Derivate der benzoesaeure, herstellungsverfahren und anwendung in desinfizierenden und konservierenden arzneimitteln. | |
| DE69030502D1 (de) | Cephalosporinverbindungen und deren herstellung | |
| KR900701278A (ko) | 바이러스 감염 치료용 담즙산 | |
| EP0242559A3 (de) | Verwendung aminosubstituierter Benzoesäuren als Heilmittel gegen Diarrhoe und Arzneimittel auf Basis dieser Verbindungen | |
| ATE40521T1 (de) | Verwendung eines substanzgemisches fuer die herstellung eines mittels gegen buergers krankheit. | |
| ATE24834T1 (de) | Verwendung von beta-(1-adamantyl)-alpha, alphadimethylethylamin zur herstellung eines arzneimittels zur behandlung von otitis externa bei hunden. | |
| FI791976A (fi) | Nya n1-bensoyl-n2-fenyl-1,3-diaminopropan-2-oler och deras salter foerfarande foer framstaellning av dessa samt laekemedel innehaollande dessa foereningar | |
| DE69819002D1 (de) | Polyhydroxyalkylpyrazine derivate,deren herstellung und diese enthaltende arzneimitteln | |
| DE59008715D1 (de) | 2-Formylbenzylphosphonsäure-Derivate, deren Herstellung und ihre Verwendung zur Behandlung von durch Viren verursachte Krankheiten. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification | ||
| EEIH | Change in the person of patent owner | ||
| REN | Ceased due to non-payment of the annual fee |